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Summary Trimelamol (N2,N4,N6-trihydroxymethyl-N2,N4,N6-trimethylmelamine) is an analogue of penta-
methylmelamine (PMM). In early clinical trials PMM failed to show significant anti-tumour activity in man
which was attributed to poor metabolic activation. Trimelamol does not require activation and is therefore
expected to be more active in man. PMM caused dose-limiting emesis and sedation whereas Trimelamol is
much less neurotoxic in rodents. The relative penetration of PMM and Trimelamol into mouse brain has
therefore been examined. Mice receiving PMM at 90mgkg-1 i.p. were found to have high concentrations of
the drug in the CNS compared to plasma (mean brain/plasma ratio 1.04) whereas animals receiving
Trimelamol had consistently low CNS concentrations (mean brain/plasma ratio 0.08). This difference did not
correlate with plasma protein binding which is greater for PMM (68.2%) than for Trimelamol (17.5%).
However, it does appear to be related to lipophilicity. In Phase I clinical trial Trimelamol has proved much
less emetic than PMM and causes no acute sedation. It is likely that this reduction in toxicity may be
explained by the relatively poor ability ofTrimelamol to enter the CNS.
N2,N4,N6-trihydroxymethyl-N2,N4,N6-trimethyl-
melamine (Trimelamol, CB1O-375) is an analogue
of hexamethylmelamine (HMM) which has recently
entered clinical trial. HMM is a synthetic s-triazine
which showed broad-spectrum, if modest, activity
in extensive clinical trials (Blum et al., 1978; Legha
et al., 1976). It caused severe emesis and yet had to
be given by mouth. Pentamethylmelamine (PMM)
which is more water-soluble, was introduced in the
hope that parenteral administration would alleviate
the gastrointestinal toxicity. Unfortunately it
proved to be even more emetic than HMM,
indicating that this was a centrally mediated effect,
and also caused severe sedation, even coma. These
factors proved dose-limiting (Casper et al., 1981;
Goldberg et al., 1980; Ihde et al., 1981; Muindi et
al., 1983; Van Echo et al., 1980). Anti-tumour
activity in these Phase I trials was also
disappointing.
HMM and PMM require metabolic activation in
order to express significant cytotoxic activity in
vitro (Rutty & Connors, 1977). The inhibitory effect
of non-activated HMM and PMM can be reversed
by removing the drug (Rutty et al., 1983). However
N-hydroxymethylmelamines, such as are formed
during activation (Borkovec & DeMilo, 1967) are
significantly more toxic in vitro (Rutty & Abel,
Correspondence: I.R. Judson.
Received 1 November 1985; and in revised form, 7
January 1986.
1980) and their effect is not reversed by drug
removal (Rutty et al., 1983).
Pharmacokinetic studies with PMM showed that
metabolic activation occurred only very slowly in
man compared with rodents and that this might
account for its poor clinical activity (Rutty et al.,
1982). Trimelamol was therefore developed for
clinical use since, as a melamine bearing N-
hydroxymethyl groups, it does not require
metabolic activation.
It had been noted that Trimelamol caused
markedly less sedation than PMM in rodents
(Newell et al., 1983). The pharmacokinetics of
Trimelamol and PMM in plasma and whole brain
were therefore investigated in the mouse to see
whether the brain levels achieved would correlate
with the observed differences in neurotoxicity.
Plasma protein binding and lipophilicity were
examined in an attempt to explain these findings.
Materials and methods
Chemicals
PMM was synthesised by Prof. W.C.J. Ross at the
Chester Beatty Research Institute. Trimelamol was
synethesised by Warner-Lambert (Ann Arbor,
Michigan, USA) for the NCI (NSC 283162).
Analytical grade reagents used in HPLC and
preparation of buffers were supplied by May and
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Baker Ltd. (Dagenham, Essex, UK), BDH
Chemicals Ltd. (Poole, Dorset, UK), and Fisons
Ltd. (Loughborough, Leics, UK). Cremophor
EL(R) was obtained from Sigma Chemical Co. Ltd.
(Poole, Dorset, UK).
HPLC
High performance liquid chromatography (HPLC)
was performed using a Waters Associates Model
ALC/GPC204 chromatograph (Waters Associates,
Milford, Mass., USA) equipped with a model 480
variable wavelength detector. The method for
analysing PMM (CB1O-370), N2 -hydroxymethyl-N2,
N4, N4, N6, N6-pentamethylmelamine (HMPMM,
CBIO-369) and N2, N4-dihydroxymethyl-N2,
N4, N6, N6-tetramethylmelamine (DHMtetraMM,
CB1O-419) utilised a 15cmx4.6mm column con-
taining Spherisorb 5pm hexyl (C6) packing (Phase
Sep Ltd., Queensferry, Clwyd, UK) protected by a
6.5x2.1mm precolumn containing Co:PELL ODS
packing (Whatman Ltd., Maidstone, Kent, UK).
Isocratic elution was carried out with 50%
methanol/50% ammonium formate at pH 6.3
running at 1.5mlmin-1. Detection was by UV
absorption at 225nm, and peaks were quantified by
electronic integration using a Trilab II data analysis
system (Trivector Scientific Ltd., Sandy, Beds.,
UK). Twenty-fiveMl samples were injected
automatically and the samples kept at 4°C. The
separation was carried out at a constant
temperature of 16°C.
The HPLC for Trimelamol used an octyl (C8)
packing material and isocratic elution at
2.Omlmin-' with 30% methanol/70% 0.05M
ammonium bicarbonate pH 8.1. Detection was
similarly by UV absorption at 225nm.
Finally N2,N4,N6-trimethylmelamine (TriMM)
was analysed using a C8 column and isocratic
elution at 2.0mlmin-1 with 9% acetonitrile/91%
0.05 M ammonium bicarbonate. Detection was by
UV absorbtion at 225 nm.
Pharmacokinetics
Male Balb C- mice, body weight 20-28g were
treated with PMM or Trimelamol at a dose of
90mgkg-1, the ED90 versus the PC6 tumour
(Rutty et al., 1985). The drugs were dissolved in
DMSO and diluted with 5% dextrose pH 7.4 to
give a drug concentration of 4.5mgml-1 and
DMSO concentration of 5%. The drugs were
administered intraperitoneally (i.p.), three mice per
time point, at a constant volume of 0.2ml per 0g
body weight. At regular intervals 5-60min
following injection, mice were anaesthetised with
diethyl ether and blood withdrawn by direct cardiac
puncture using pre-cooled syringes. The blood was
placed in heparinised ice-cold tubes and centrifuged
at 1800g and 4°C for 10min. The plasma was
precipitated with 2vol ice-cold methanol and again
spun for 10min at 4°C. The supernatant was
removed and analysed by HPLC. After bleeding the
animals were killed, the brains removed and placed
in 10ml ice-cold isotonic KCl solution (1.15%).
The brains were washed in further KCl solution,
blotted dry, weighed and hand-homogenised on ice
in 4vol (4mlg-1 wet tissue) 1.15% KCl. The
suspension was precipitated with 2vol ice-cold
methanol, spun at 1800g and 4°C for 10min and
this supernatant also analysed by HPLC. Standards
were prepared in human plasma.
A single time point experiment was also
performed to investigate the effect of a surfactant
formulation on the CNS uptake of Trimelamol.
The drug was given i.v. at 230mgkg-1, dissolved
either in 5% dextrose pH 7.4 at 4.5mgml-1 or in
10% Cremophor EL/5% dextrose pH 7.4 at the
same concentration. Three mice were treated with
each formulation and plasma and brain samples
obtained 30min after injection and prepared as
above.
The exponential function C=Ae-p' (where C is
the drug plasma concentration, A the constant, P
the first-order rate constant and t the time after the
end of drug administration) was fitted to the data
by a non-linear least squares method in order to
determine the half-lives (Dixon, 1980).
Stability of Trimelamol
The stability of Trimelamol at room temperature
was measured in 5% dextrose pH 7.4 and in 10%
Cremophor/dextrose pH 7.4. Serial estimations
were performed by HPLC at intervals of 15-30min
over 5h. The first order rate constants and half-
lives were calculated as described above.
Plasma protein binding
The plasma protein binding of PMM, Trimelamol,
HMPMM, DHtetraMM and TriMM was deter-
mined by ultrafiltration using the Amicon micro-
partition system (Amicon Corporation, Danvers,
Mass., USA). The drugs were dissolved in
water or DMSO and then diluted in human plasma
or water to give a final drug concentration of
100 igml-1 and varying DMSO concentrations of
5%, 0.1% or 0%. Each assay was performed in
triplicate and consisted of incubation at 37°C for
3min followed by centrifugation in ultrafiltration
chambers containing YMB protein elimination
filters at 2000g and 15°C for 10min. Owing to
the chemical instability of N-hydroxymethyl-
melamines control samples were also prepared in
plasma and treated identically apart from ultra-LOW CNS PENETRATION OF TRIMELAMOL 603
filtration in order to correct for chemical breakdown
during the procedure. The water controls were
performed in order to exclude a possible error due
to binding of drug to the filters. The ultrafiltrates
and controls were mixed with 2vol ice-cold methanol
and spun at 1800g and 4°C for Omin. The samples
were analysed using the HPLC assays described
above. Protein binding was calculated as plasma
concentration minus ultrafiltrate concentration/
plasma concentration x 100%.
Results
The brain and plasma concentration profiles for
PMM and Trimelamol following i.p. administration
at 90mgkg-1 are shown in Figures 1 and 2, and
summarised in Table I. The concentration of PMM
in mouse brain was found to closely match the
plasma concentration at all times and a mean value
of 1.04 was obtained for the brain/plasma ratio. In
contrast the Trimelamol brain concentration rose
slowly over 30min but never exceeded 1 Mgg-1.
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Figure 1 Plasma (-*-), and brain (- - A--),
pharmacokinetics of PMM 90mgkg-1 i.p. in Balb C-
mice.
and brain (A), pharmaco-
90mgkg- I i.p. in Balb C-
The values obtained may be overestimates, since a
small amount of contamination would have
occurred due to blood in the cerebral vessels. In
addition such small concentrations were close to the
limits of detection of the assay. The mean
brain/plasma ratio over 60min was <0.1.
The brain and plasma concentrations of
Trimelamol following i.v. administration at
230mgkg-1 in 5% dextrose or 10% Cremophor/
dextrose are summarised in Table II. Although a
dose-related increase in plasma and brain
concentration at 30min was observed, the
brain/plasma ratio was little elevated at 0.14 for the
5% dextrose formulation. Administration of the
drug in 10% Cremophor resulted in profound acute
sedation, and much higher concentration of
Trimelamol in both brain and plasma were
observed. The brain/plasma ratio at 30min was
unchanged at 0.15.
Trimelamol was quite stable in 5% dextrose at
pH 7.4 and room temperature with an elimination
half-life of 417.5min (±6.3s.e.). However the
addition of 10% Cremophor stabilised the drug still wwwww
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Table I Plasma and brain concentrations of PMM and Trimelamol in Balb C- mice following bolus injection at
90mgkg1 i.p.
Plasma conc. Brain conc. Mean brainl
Peak plasma conc. at 30 min Plasma tl2f Peak brain conc. at 30 min plasma ratio
Drug (pgml-1) (ugml-1) (min) (pgg-1) (1ugg-1) over 60 min
PMM 18.0 (±1.O) 1.7 (±1.O) 7.1 (+0.6) 25.7 (±0.9) 1.25 (+0.12) 1.04 (±0.2)
(5 min) (5 min) (range 0.5-1.6)
Trimelamol 33.8 (±6.0) 4.7 (+0.7) 8.8 (+1.1) 0.54 (±0.14) 0.54 (+0.14) 0.008 (±0.07)
(5 min) (30 min) (range 0.002-0.5)
aConcentrations given are mean values from 3 animals ( s.e.).
Table II CNS penetration of Trimelamol 230 mgkg- 1 i.v.
Cremophor EL
Effect of 10%
Plasma conc. Brain conc.
Formulation at 30 min at 30 min Brain/plasma
vehicle (jgml-)a t(Pgg-1) ratio
5% Dextrose
10% Cremophor/Dextrose
26.4 (±2.8) 3.8 (+0.9) 0.14 (+0.02)
70.3 (±5.8) 10.8 (±1.0) 0.15 (±0.003)
aConcentrations given are mean values from 3 animals (± s.e.).
further giving a t1l2f of 730.6min (±34.2s.e.), i.e.
an increase of 75%.
The results of the plasma protein binding studies
are given in Table Illa and show that Trimelamol
is much less strongly protein bound than PMM, i.e.
only 16.8% compared with 68.2%. It is apparent
that protein binding is proportional to the number
of methyl groups on the melamine ring. Repeat
experiments in the presence of DMSO showed no
significant effect on the protein-binding of PMM
and no effect on that of Trimelamol, see Table IlIb.
Neither drug bound to the protein elimination
filters.
Discussion
A marked difference was found in the ability of
PMM and Trimelamol to penetrate the CNS of
mice. PMM appeared to enter the brain rapidly
with no detectable lag phase. Trimelamol, in
contrast, entered the brain very poorly, its
concentration never exceeding 1 ggg 1. Precise
conclusions about the kinetics of Trimelamol in the
CNS are difficult to draw owing to the limits of
accuracy of this experiment. However, it is clear
that for PMM the brain/plasma ratio of - 1.0
indicates the lack of a 'blood-brain barrier' for this
drug whereas Trimelamol is largely excluded from
the CNS.
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Table lia Plasma protein binding of melamines
% Protein
Drug RI R2 R3 binding
PMM H CH3 CH3 68.2
HMPMM CH2OH CH3 CH3 63.0
DHM-tetraMM CH2OH CH2OH CH3 36.2
Trimelamol CH2OH CH2OH CH2OH 16.8
TriMM H H H 13.0
Table IlIb Effect of DMSO on plasma protein
binding
Plasma protein binding
(%)
DMSO conc. (%) Trimelamol PMM
0 16.8 68.2
0.1 14.6 71.2
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Figure 3 Structures and partition coefficients of PMM and Trimelamol.
Stewart et al. (1983) found high levels of PMM
and its metabolites in human brain tumours, but
only the metabolite, N2-monomethylmelamine, was
detectable in the adjacent normal brain. We also
found higher levels of the decomposition products
of both PMM and Trimelamol in mouse CNS
compared with the parent compounds (unpublished
data). However, as Stewart et al. indicated, the
abnormal blood supply to cerebral tumour causes
disruption of the blood-brain barrier. Therefore
their findings are not directly comparable, and the
dose of PMM used in their studies was very small.
This difference in CNS penetration between
PMM and Trimelamol correlates very well with the
consistently observed difference in neurotoxicity
between the two drugs. PMM causes marked
sedation in mice and rats and impairs the righting
reflex whereas Trimelamol causes little or no
sedation even at the maximum tolerated dose
(Rutty et al., 1985).
The effect of Cremophor EL on the CNS
penetration of Trimelamol was investigated
following the observation that its use in
formulation was associated with an increase in
neurotoxicity. Mice given Trimelamol in 10%
Cremophor/5% dextrose became acutely sedated
and sometimes fitted. On recovery the animals
remained hypokinetic and rather ataxic for some
hours. This was associated with an increase in early
deaths but no change in the actual LD50
(unpublished observations). The increase in neuro-
toxicity was confirmed in these experiments which
were performed at 230mgkg- , a lethal dose of
Trimelamol known to cause mild sedation. The
increase in Trimelamol brain concentration in the
presence of Cremophor was therefore expected.
Other surfactants, e.g. polysorbate 80, are known
to change the volume of distribution of certain
drugs and may enhance their uptake into the CNS
possibly by disrupting the blood-brain barrier
(Azmin et al., 1985). The reason for the increase in
plasma concentration at 30min is unclear. We
found that the in vitro half-life of Trimelamol in
5% dextrose pH 7.4 was increased by 75% with the
addition of 10% Cremophor. However, we have
not confirmed that this also leads to an increase in
the in vivo half-life. Whilst conferring some
advantages in terms of solubility and stability the
use of this particular surfactant was clearly
associated with an unacceptable increase in
Trimelamol neurotoxicity.
In conclusion the CNS penetration of
Trimelamol is significantly less than that of PMM.
This difference is clearly not due to a difference in
plasma protein binding since PMM is much more
highly protein bound, and the use of DMSO in the
pharmacokinetic experiments would not have
interfered with this. An explanation is more likely
to be found in the marked differences in
lipophilicity between the two compounds. Figure 3
shows the chemical structures and values for the
octanol/water partition coefficients for PMM and
Trimelamol as determined by Cumber & Ross
(1977). The relatively low lipophilicity of
Trimelamol seems likely to be responsible for its
reduced CNS penetration and hence reduced neuro-
toxicity. In a Phase I trial at the Royal Marsden
Hospital the drug has proved less emetic than
PMM in man and causes little or no sedation, as
well as showing encouraging signs of anti-tumour
activity.606 I.R. JUDSON et al.
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